Want to see IPHA full AI Analyst Report?
IPHA Stock Chart & Stats
$1.78
$0.02(1.14%)
At close: 4:00 PM EDT
$1.78
$0.02(1.14%)
Day’s Range― - ―
52-Week Range$1.17 - $2.62
Previous Close$1.74
Volume2.54K
Average Volume (3M)386.19K
Market Cap
$165.75M
Enterprise Value$150.19
Total Cash (Recent Filing)$34.30M
Total Debt (Recent Filing)$22.56M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Sep 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding93,921,860
10 Day Avg. Volume29,239
30 Day Avg. Volume386,189
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-6.14
Price to Sales (P/S)47.79
P/FCF Ratio-3.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside265.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$24.32M
Bulls Say, Bears Say
Bulls Say
High-value Partnership And Milestone EconomicsLarge, structured collaboration economics with AstraZeneca provide durable non-dilutive funding pathways (milestones, royalties, potential profit-share). These contracts transfer development and commercialization risk, give access to partner resources, and materially expand optionality for funding late‑stage programs over months.
Regulatory Clearance For Lacutamab Phase IIIFormal FDA clearance and multiple expedited designations establish a clear registrational path and compress regulatory uncertainty. This status improves the program's long-term de-risking: it clarifies endpoints and timelines and increases the odds of accelerated review or prioritized regulatory engagement if clinical outcomes align.
Completed Large Phase III Enrollment (PACIFIC-9)A fully enrolled, AstraZeneca-led Phase III reduces execution risk and creates a near-term, high-impact readout that can trigger partner decisions and milestone payments. Completion of enrollment materially increases the visibility of program outcomes and preserves optionality for development or partnering over the coming months.
Bears Say
Negative Shareholders' EquityNegative equity reflects cumulative losses and materially weakens solvency metrics. It constrains financing options, elevates creditor and covenant sensitivity, and increases the likelihood of dilution or less-favorable refinancing terms—structural headwinds that persist until profitability or recapitalization occurs.
Tight Cash Runway And Funding RiskA runway to end‑Q3 2026 creates a lasting financing imperative: management must secure partnerships, milestone receipts, or external capital to initiate late‑stage trials. This structural timing pressure can delay programs, force concessions on deal economics, or increase dilution risk if markets or partner options are constrained.
Low Recurring Revenue Vs High Operating SpendA business model reliant on sporadic licensing/grant receipts while bearing persistently high R&D and G&A creates structural volatility in funding and planning. Limited internal revenue reduces self‑funding capacity, heightens dependency on external partners or financing, and weakens medium-term predictability of operations.
Innate Pharma News
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.17 and its highest was $2.62 in the past 12 months.
What is Innate Pharma’s market cap?
Innate Pharma’s market cap is $165.75M.
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Sep 17, 2026 which is in 46 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Mar 26, 2026. The company reported -$0.358 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.216.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -0.21.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 93,921,860 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.358 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innate Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (265.17% Upside)
$6.50 (265.17% Upside)
Blogger Sentiment
Bullish
IPHA Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.95%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma S.A. (IPHA) is a clinical-stage biotechnology company focused on immuno-oncology, developing therapeutics that leverage the innate immune system—particularly natural killer (NK) cells and related immune checkpoints—to treat cancer. Its portfolio includes monoclonal antibodies and antibody-drug conjugate (ADC) programs, with clinical and preclinical candidates targeting immune receptors and tumor-associated antigens, and it operates through internal R&D and collaborations with larger biopharmaceutical partners.
IPHA Company Deck
IPHA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call featured multiple meaningful clinical and regulatory milestones (FDA clearance for lacutamab Phase III, completed PACIFIC-9 enrollment, encouraging early IPH4502 data, and high-value partnership milestone potential) and demonstrated cost discipline with lower R&D spend. Offsetting these positives are material near-term financing and execution risks: modest reported revenue (EUR 9M), a high burn rate (EUR 63M operating expenses), and a limited cash runway (EUR 44.8M through Q3 2026) that makes initiation of late-stage programs dependent on partner deals or other financing. Clinical data are promising but still early and need confirmation. Overall, the company shows strong programmatic momentum and partnership upside, but material funding and timing risks balance that optimism.View all IPHA earnings summariesIPHA Stock 12 Month Forecast
Average Price Target
$6.50
▲(265.17% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors